Dysfibrinogenemia: From molecular anomalies to clinical manifestations and management

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 909-919

  Casini, A ^a   Neerman Arbez, M ^b   Ariens R A ^c   de Moerloose, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Bleeding; Congenital; Dysfibrinogenemia; Fibrinogen; Pregnancy; Thrombosis

Indexed keywords

ANTIGEN; BATROXOBIN; FIBRIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; FIBRINOGEN VARIANT;

ARTICLE; BLEEDING; CESAREAN SECTION; CLINICAL FEATURE; CRYOPRECIPITATE; DYSFIBRINOGENEMIA; FGA GENE; FGG GENE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MISSENSE MUTATION; PARTIAL THROMBOPLASTIN TIME; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; SPONTANEOUS ABORTION; THROMBIN TIME; THROMBOSIS; VISCOELASTICITY; AFIBRINOGENEMIA; ANIMAL; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; MALE; METABOLISM; MOLECULAR DIAGNOSIS; MUTATION; PHENOTYPE; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROGNOSIS; RISK FACTOR;

AFIBRINOGENEMIA; ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DNA MUTATIONAL ANALYSIS; FEMALE; FIBRINOGENS, ABNORMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROGNOSIS; RISK FACTORS; THROMBOSIS;

EID: 84930503578     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12916     Document Type: Article

References (100)

1. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39: 585-95.
2. Imperato C, Dettori AG. Congenital hypofibrinogenemia with fibrinoasthenia. Helv Paediatr Acta 1958; 13: 380-99.
3. Blomback M, Blomback B, Mammen EF, Prasad AS. Fibrinogen Detroit - a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature 1968; 218: 134-7.
4. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-904.
5. Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121: 1712-19.
6. Soria J, Soria C, Caen P. A new type of congenital dysfibrinogenaemia with defective fibrin lysis - Dusard syndrome: possible relation to thrombosis. Br J Haematol 1983; 53: 575-86.
7. Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, Sakata Y. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 2006; 4: 1738-46.
8. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9: 1687-704.
9. Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126: e428-33.
10. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-61.
11. Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, Gautier P, Biron C, Neerman-Arbez M, de Moerloose P. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125: 553-61.
12. Brennan SO, Mosesson MW, Lowen R, Frantz C. Dysfibrinogenemia (fibrinogen Wilmington) due to a novel Aalpha chain truncation causing decreased plasma expression and impaired fibrin polymerisation. Thromb Haemost 2006; 96: 88-9.
13. de Raucourt E, Fischer AM, Meyer G, de Mazancourt P. A Bbeta 14 Arg -> Cys fibrinogen variant in a patient with thrombotic complications (fibrinogen St-Germain III). J Thromb Haemost 2006; 4: 2722-3.
14. Dempfle CE, George PM, Borggrefe M, Neumaier M, Brennan SO. Demonstration of heterodimeric fibrinogen molecules partially conjugated with albumin in a novel dysfibrinogen: fibrinogen Mannheim V. Thromb Haemost 2009; 102: 29-34.
15. Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126: 499-505.
16. Ebert RF. Index of Variant Human Fibrinogens. Boca Raton, Ann Arbor, Boston: CRC Press, 1994.
17. Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, Mumford AD. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160: 220-7.
18. Krammer B, Anders O, Nagel HR, Burstein C, Steiner M. Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res 1994; 76: 577-9.
19. Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res 2012; 130(Suppl. 2): S7-11.
20. Llamas P, Santos AB, Outeirino J, Soto C, Tomas JF. Diagnostic utility of comparing fibrinogen Clauss and prothrombin time derived method. Thromb Res 2004; 114: 73-4.
21. Loreth RM, Meyer M, Albert FW. Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg->cys substitution. Haemostasis 2001; 31: 12-17.
22. Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol 2000; 63: 149-55.
23. Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH. Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatr Blood Cancer 2013; 60: 500-2.
24. Thorsen LI, Brosstad F, Solum NO, Stormorken H. Increased binding to ADP-stimulated platelets and aggregation effect of the dysfibrinogen Oslo I as compared with normal fibrinogen. Scand J Haematol 1986; 36: 203-10.
25. Ariens RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11(Suppl. 1): 294-305.
26. Galanakis DK, Neerman-Arbez M, Brennan S, Rafailovich M, Hyder L, Travlou O, Papadakis E, Manco-Johnson MJ, Henschen A, Scharrer I. Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications. Thromb Res 2014; 133: 1115-23.
27. Kalina U, Stohr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, Peyvandi F. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis 2008; 19: 777-83.
28. Brennan SO, Mangos H, Faed JM. Benign FGB (148Lys->Asn, and 448Arg->Lys), and novel causative gamma211Tyr->His mutation distinguished by time of flight mass spectrometry in a family with hypofibrinogenaemia. Thromb Haemost 2014; 111: 679-84.
29. Lounes KC, Soria C, Mirshahi SS, Desvignes P, Mirshahi M, Bertrand O, Bonnet P, Koopman J, Soria J. Fibrinogen Ales: a homozygous case of dysfibrinogenemia (gamma-Asp(330)->Val) characterized by a defective fibrin polymerization site 'a'. Blood 2000; 96: 3473-9.
30. Niwa K, Takebe M, Sugo T, Kawata Y, Mimuro J, Asakura S, Sakata Y, Mizushima J, Maeda A, Endo H, Matsuda M. A gamma Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood 1996; 87: 4686-94.
31. Kotlin R, Suttnar J, Capova I, Hrachovinova I, Urbankova M, Dyr JE. Fibrinogen Sumperk II: dysfibrinogenemia in an individual with two coding mutations. Am J Hematol 2012; 87: 555-7.
32. Westbury SK, Duval C, Philippou H, Brown R, Lee KR, Murden SL, Phillips E, Reilly-Stitt C, Whalley D, Ariens RA, Mumford AD. Partial deletion of the alphaC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis. Thromb Haemost 2013; 110: 1135-44.
33. Furlan M, Steinmann C, Jungo M, Bogli C, Baudo F, Redaelli R, Fedeli F, Lammle B. A frameshift mutation in exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III. J Biol Chem 1994; 269: 33129-34.
34. Okumura N, Terasawa F, Takezawa Y, Hirota-Kawadobora M, Inaba T, Fujita N, Saito M, Sugano M, Honda T. Heterozygous Bbeta-chain C-terminal 12 amino acid elongation variant, BbetaX462W (Kyoto VI), showed dysfibrinogenemia. Blood Coagul Fibrinolysis 2012; 23: 87-90.
35. Rosenberg JB, Newman PJ, Mosesson MW, Guillin MC, Amrani DL. Paris I dysfibrinogenemia: a point mutation in intron 8 results in insertion of a 15 amino acid sequence in the fibrinogen gamma-chain. Thromb Haemost 1993; 69: 217-20.
36. Neerman-Arbez M, de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U, eds. Williams Hematology, 8th edn. New York, NY: McGraw-Hill, 2010:1-33.
37. Hogan KA, Gorkun OV, Lounes KC, Coates AI, Weisel JW, Hantgan RR, Lord ST. Recombinant fibrinogen Vlissingen/Frankfurt IV. The deletion of residues 319 and 320 from the gamma chain of fibrinogen alters calcium binding, fibrin polymerization, cross-linking, and platelet aggregation. J Biol Chem 2000; 275: 17778-85.
38. Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA->stop TAA). Blood 1992; 80: 1972-9.
39. Park R, Ping L, Song J, Hong SY, Choi TY, Choi JR, Gorkun OV, Lord ST. Fibrinogen residue gammaAla341 is necessary for calcium binding and 'A-a' interactions. Thromb Haemost 2012; 107: 875-83.
40. Galanakis D. Afibrinogenemias and dysfibrinogenemias. In: Marder V, White GC, Aird WC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2012: 693-708.
41. Hill M, Dolan G. Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias. Haemophilia 2008; 14: 889-97.
42. Lane DA, Southan C, Ireland H, Thompson E, Kehl M, Henschen A. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide. Br J Haematol 1983; 53: 587-97.
43. Galanakis DK, Neerman-Arbez M, Scheiner T, Henschen A, Hubbs D, Nagaswami C, Weisel JW. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release. Blood Coagul Fibrinolysis 2007; 18: 731-7.
44. Galanakis DK, Henschen A, Peerschke EI, Kehl M. Fibrinogen Stony Brook, a heterozygous A alpha 16Arg-Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly. J Clin Invest 1989; 84: 295-304.
45. Flood VH, Al-Mondhiry HA, Farrell DH. The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance. Br J Haematol 2006; 134: 220-6.
46. Alving BM, Henschen AH. Fibrinogen giessen I: a congenital homozygously expressed dysfibrinogenemia with A alpha 16 Arg-His substitution. Am J Hematol 1987; 25: 479-82.
47. Mosesson MW, DiOrio JP, Muller MF, Shainoff JR, Siebenlist KR, Amrani DL, Homandberg GA, Soria J, Soria C, Samama M. Studies on the ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin). Blood 1987; 69: 1073-81.
48. Cote HC, Lord ST, Pratt KP. gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen. Blood 1998; 92: 2195-212.
49. Mosesson MW, Siebenlist KR, DiOrio JP, Matsuda M, Hainfeld JF, Wall JS. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg->Cys). J Clin Invest 1995; 96: 1053-8.
50. Ishikawa S, Hirota-Kawadobora M, Tozuka M, Ishii K, Terasawa F, Okumura N. Recombinant fibrinogen, gamma275Arg->Cys, exhibits formation of disulfide bond with cysteine and severely impaired D:D interactions. J Thromb Haemost 2004; 2: 468-75.
51. Hirota-Kawadobora M, Terasawa F, Suzuki T, Tozuka M, Sano K, Okumura N. Comparison of thrombin-catalyzed fibrin polymerization and factor XIIIa-catalyzed cross-linking of fibrin among three recombinant variant fibrinogens, gamma 275C, gamma 275H, and gamma 275A. J Thromb Haemost 2004; 2: 1359-67.
52. Terasawa F, Hogan KA, Kani S, Hirose M, Eguchi Y, Noda Y, Hongo M, Okumura N. Fibrinogen Otsu I: a gammaAsn319, Asp320 deletion dysfibrinogen identified in an asymptomatic pregnant woman. Thromb Haemost 2003; 90: 757-8.
53. Meh DA, Mosesson MW, Siebenlist KR, Simpson-Haidaris PJ, Brennan SO, DiOrio JP, Thompson K, Di Minno G. Fibrinogen naples I (B beta A68T) nonsubstrate thrombin-binding capacities. Thromb Res 2001; 103: 63-73.
54. Collet JP, Soria J, Mirshahi M, Hirsch M, Dagonnet FB, Caen J, Soria C. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-9.
55. Meyer M, Franke K, Richter W, Steiniger F, Seyfert UT, Schenk J, Treuner J, Haberbosch W, Eisert R, Barthels M. New molecular defects in the gamma subdomain of fibrinogen D-domain in four cases of (hypo)dysfibrinogenemia: fibrinogen variants Hannover VI, Homburg VII, Stuttgart and Suhl. Thromb Haemost 2003; 89: 637-46.
56. Robert-Ebadi H, Le Querrec A, de Moerloose P, Gandon-Laloum S, Borel D, Neerman-Arbez M. A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis. Blood Coagul Fibrinolysis 2008; 19: 697-9.
57. Kotlin R, Pastva O, Stikarova J, Hlavackova A, Suttnar J, Chrastinova L, Riedel T, Salaj P, Dyr JE. Two novel mutations in the fibrinogen gamma nodule. Thromb Res 2014; 134: 901-8.
58. Weisel JW. Why dysfibrinogenaemias still matter. Thromb Haemost 2009; 102: 426-7.
59. Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90.
60. Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis 2010; 21: 35-40.
61. Santacroce R, Cappucci F, Pisanelli D, Perricone F, Papa ML, Santoro R, Grandone E, Margaglione M. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group. Blood Coagul Fibrinolysis 2006; 17: 235-40.
62. Rein CM, Anderson BL, Ballard MM, Domes CM, Johnston JM, Madsen RJ Jr, Wolper KK, Terker AS, Strother JM, Deloughery TG, Farrell DH. Severe bleeding in a woman heterozygous for the fibrinogen gammaR275C mutation. Blood Coagul Fibrinolysis 2010; 21: 494-7.
63. Siebenlist KR, Prchal JT, Mosesson MW. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg-His) containing heterodimeric molecules. Blood 1988; 71: 613-18.
64. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126: 1387-90.
65. Shen YM, Trang V, Sarode R, Brennan S. Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system. Blood Coagul Fibrinolysis 2014; 25: 392-4.
66. Tarumi T, Martincic D, Thomas A, Janco R, Hudson M, Baxter P, Gailani D. Familial thrombophilia associated with fibrinogen paris V: Dusart syndrome. Blood 2000; 96: 1191-3.
67. Ramanathan R, Gram J, Feddersen S, Nybo M, Larsen A, Sidelmann JJ. Dusart syndrome in a Scandinavian family characterized by arterial and venous thrombosis at young age. Scand J Clin Lab Invest 2013; 73: 585-90.
68. Carrell N, Gabriel DA, Blatt PM, Carr ME, McDonagh J. Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 1983; 62: 439-47.
69. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
70. Travlou A, Gialeraki A, Merkouri E, Politou M, Sfyridaki A, Neerman-Arbez M. Coexisting dysfibrinogenemia (gamma Arg275His) and FV Leiden associated with thrombosis (Fibrinogen Crete). Thromb Res 2010; 126: e162-4.
71. Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11: 293-304.
72. Morris TA, Marsh JJ, Chiles PG, Magana MM, Liang NC, Soler X, Desantis DJ, Ngo D, Woods VL Jr. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114: 1929-36.
73. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, Collins PW, Kitchen S, Dolan G, Mumford AD. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
74. Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, Mainwaring J, Mathias M, O'Connell N, BCSH Committee Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167: 304-26.
75. Peyvandi F, Bidlingmaier C, Garagiola I. Management of pregnancy and delivery in women with inherited bleeding disorders. Semin Fetal Neonatal Med 2011; 16: 311-17.
76. de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther 2008; 8: 979-92.
77. Bevan DH. Cryoprecipitate: no longer the best therapeutic choice in congenital fibrinogen disorders? Thromb Res 2009; 124(Suppl. 2): S12-16.
78. Pike GN, Bolton-Maggs PH. Factor deficiencies in pregnancy. Hematol Oncol Clin North Am 2011; 25: 359-78 viii-ix.
79. Iwaki T, Sandoval-Cooper MJ, Paiva M, Kobayashi T, Ploplis VA, Castellino FJ. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse. Am J Pathol 2002; 160: 1021-34.
80. Snir A, Brenner B, Paz B, Ohel G, Lanir N. The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreading. Thromb Res 2013; 132: 477-83.
81. Pretorius E, Bronkhorst P, Briedenhann S, Smit E, Franz RC. Comparisons of the fibrin networks during pregnancy, nonpregnancy and pregnancy during dysfibrinogenaemia using the scanning electron microscope. Blood Coagul Fibrinolysis 2009; 20: 12-16.
82. Miesbach W, Galanakis D, Scharrer I. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis 2009; 20: 366-70.
83. Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril 2003; 79: 577-84.
84. Yamanaka Y, Takeuchi K, Sugimoto M, Sato A, Nakago S, Maruo T. Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 2003; 82: 972-3.
85. Franchini M, Raffaelli R, Musola M, Memmo A, Poli G, Franchi M, Pizzolo G, Veneri D. Management of inherited dysfibrinogenemia during pregnancy: a description of four consecutive cases. Ann Hematol 2007; 86: 693-4.
86. Mathonnet F, Guillon L, Detruit H, Mazmanian GM, Dreyfus M, Alvarez JC, Giudicelli Y, de Mazancourt P. Fibrinogen Poissy II (gammaN361K): a novel dysfibrinogenemia associated with defective polymerization and peptide B release. Blood Coagul Fibrinolysis 2003; 14: 293-8.
87. Kotlin R, Zichova K, Suttnar J, Reicheltova Z, Salaj P, Hrachovinova I, Dyr JE. Congenital dysfibrinogenemia Aalpha Gly13Glu associated with bleeding during pregnancy. Thromb Res 2011; 127: 277-8.
88. Meldrum DJ, Evans G, Popham P. Spinal anaesthesia and dysfibrinogenaemia. Int J Obstet Anesth 2001; 10: 64-7.
89. Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, Siebenlist KS, Legrand C, Soria J, Soria C, Caen JP. Molecular basis for fibrinogen Dusart (A alpha 554 Arg->Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91: 1637-43.
90. Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg->Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood 1994; 84: 3709-14.
91. Marchi R, Lundberg U, Grimbergen J, Koopman J, Torres A, de Bosch N, Haverkate F, Arocha P. Fibrinogen Caracas V, an abnormal fibrinogen with an Aalpha 532 Ser->Cys substitution associated with thrombosis. Thromb Haemost 2000; 84: 263-70.
92. Koopman J, Haverkate F, Grimbergen J, Engesser L, Novakova I, Kerst AF, Lord ST. Abnormal fibrinogens IJmuiden (B beta Arg14-Cys) and Nijmegen (B beta Arg44-Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci USA 1992; 89: 3478-82.
93. Brennan SO, Hammonds B, Spearing R, George PM. Electrospray ionisation mass spectrometry facilitates detection of fibrinogen (Bbeta 14 Arg -> Cys) mutation in a family with thrombosis. Thromb Haemost 1997; 78: 1484-7.
94. Vakalopoulou S, Mille-Baker B, Mumford A, Manning R, Laffan M. Fibrinogen Bbeta14 Arg->Cys: further evidence for a role in thrombosis. Blood Coagul Fibrinolysis 1999; 10: 403-8.
95. Castaman G, Ghiotto R, Tosetto A, Rodeghiero F. Bbeta 14 Arg -> Cys variant dysfibrinogen and its association with thrombosis. J Thromb Haemost 2005; 3: 409-10.
96. Liu CY, Koehn JA, Morgan FJ. Characterization of fibrinogen New York 1. A dysfunctional fibrinogen with a deletion of B beta(9-72) corresponding exactly to exon 2 of the gene. J Biol Chem 1985; 260: 4390-6.
97. Engesser L, Koopman J, de Munk G, Haverkate F, Novakova I, Verheijen JH, Briet E, Brommer EJ. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 1988; 60: 113-20.
98. Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala-Thr. J Clin Invest 1992; 90: 238-44.
99. Bentolila S, Samama MM, Conard J, Horellou MH, Ffrench P. Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature. Ann Med Interne (Paris) 1995; 146: 575-80.
100. Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia 2009; 15: 990-1005.